Q-omics provides the consensus-scored BCL10 profile across patient tissues and cancer cell-line models. BCL10 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, BCL10 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, BCL10 RNA expression shows 19,613 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight COAD, and ACC as cancer lineages where BCL10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL10 survival associations across molecular data types. BCL10 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL10 RNA expression–survival associations across cancer types. High BCL10 expression shows unfavorable associations in KIRP, LIHC, ACC and LGG, but favorable associations in COAD and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for BCL10 RNA expression.
This table summarizes BCL10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BCL10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL10 shows lower tumor expression in COAD, KICH, READ and THCA and higher tumor expression in LIHC and LUAD. The COAD box plot shows higher BCL10 RNA expression in normal versus tumor tissue (log2 FC = −0.989, t-test p < 0.001).
This table shows molecular features associated with BCL10 in patient tissues and cancer cell lines. In patient samples, BCL10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
